Zofia Kozak

May 29, 2024 | psychiatrist.com | Zofia Kozak |Scott Aaronson

A recent New York Times article1 described favorable findings from the most recent clinical trial investigating 3,4- methylenedioxymethamphetamine (MDMA) for moderate-to-severe posttraumatic stress disorder (PTSD).2 The article described next steps in the regulatory process for MDMA, as Lykos Therapeutics (formerly Multidisciplinary Association for Psychedelic Studies, or MAPS) has compiled data from 18 phase II and III trials and submitted a new drug application (NDA) to the US Food and Drug...

Dec 18, 2023 | acsjournals.onlinelibrary.wiley.com | Johannes Thrul |Zofia Kozak |Michael A. Carducci |Albert Garcia-Romeu

Corresponding Author Johannes Thrul PhD Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA Centre for Alcohol Policy Research, La Trobe University, Melbourne, Victoria, Australia Correspondence Johannes Thrul, Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Room 887, Baltimore, MD 21205, USA.

Sep 17, 2023 | onlinelibrary.wiley.com | Glenna J. Urquhart |Saba Rouhani |Sean Allen |Zofia Kozak

INTRODUCTION Poisoning deaths are the leading cause of unintentional death in the United States, with the highest number of fatal overdoses ever recorded (100,306) occurring in the 12-month period ending in April 2021, constituting a 28.5% increase from the same period the year before.1 Most of these fatalities involve opioids,2 and recent studies show mortality rates for opioid overdoses involving benzodiazepines (BZDs) increased 10-fold from 1999 to 2017.3 In addition to being used for...